SEC Comment Letter 0000000000-23-003232 to ASLAN Pharmaceuticals Ltd (CIK 0001722926)

ASLAN Pharmaceuticals Ltd (CIK 0001722926)
Date: March 30, 2023 · CIK: 0001722926 · Accession: 0000000000-23-003232

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-270835

Date

March 30, 2023

Author

Division of Corporation Finance

Form

UPLOAD

Company

ASLAN Pharmaceuticals Ltd (CIK 0001722926)

Letter

United States securities and exchange commission logo March 30, 2023 Carl Firth, Ph.D. Chief Executive Officer ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190

Re: ASLAN Pharmaceuticals Limited Registration Statement on Form F-3 Filed March 24, File No. 333-270835

Dear Carl Firth:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          March 30, 2023

       Carl Firth, Ph.D.
       Chief Executive Officer
       ASLAN Pharmaceuticals Limited
       3 Temasek Avenue
       Level 18 Centennial Tower
       Singapore 039190

                                                        Re: ASLAN
Pharmaceuticals Limited
                                                            Registration
Statement on Form F-3
                                                            Filed March 24,
2023
                                                            File No. 333-270835

       Dear Carl Firth:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Alan
Campbell at 202-551-4224 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Carlos Ramirez
</TEXT>
</DOCUMENT>

SecProbe.io